{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T07:31:51Z","timestamp":1772177511886,"version":"3.50.1"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cystic fibrosis-related diabetes (CFRD) is the most common extra-pulmonary complication in adults with cystic fibrosis (CF) and is primarily driven by progressive beta-cell dysfunction. The impact of CFTR modulators, particularly elexacaftor\/tezacaftor\/ivacaftor (ETI), on glucose metabolism remains unclear. This study aimed to assess the effect of ETI on beta-cell function and insulin sensitivity in people with CF (pwCF) without a history of CFRD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a prospective study involving pwCF who underwent oral glucose tolerance tests (OGTT) at baseline (prior to ETI initiation) and at 6 and 18 months after starting ETI therapy. Mathematical modelling of OGTT data was used to assess beta-cell function through two physiologically distinct components of insulin secretion: derivative control (DC), reflecting the early insulin secretory response to changes in plasma glucose, and proportional control (PC), representing the insulin secretory response to prevailing glucose concentrations. PC was expressed as the stimulus\u2013response relationship between plasma glucose and insulin secretion rate (ISR) at predefined glucose levels (4.0, 5.5, 8.0, and 11.0 mmol\/L). Insulin sensitivity was estimated using the oral glucose insulin sensitivity (OGIS) index.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixty-eight pwCF (median age 20 years) were included. At baseline, 8 (11.8%) had impaired fasting glucose and 15 (22.1%) had impaired glucose tolerance. These proportions did not significantly change over time, with no new cases of diabetes. Plasma glucose at 120 minutes post-OGTT and ISR at 5.5 mmol\/L glucose decreased significantly at both 6 and 18 months. ISR at 5.5 mmol\/L glucose also decreased at 18 months, whereas DC, ISR at higher glucose levels, and OGIS values did not significantly change over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ETI therapy was not associated with reversal of existing glucose tolerance abnormalities but may contribute to preservation of beta-cell function and insulin sensitivity. This is supported by stable DC values over time, in contrast to the progressive decline typically observed in CF populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1774728","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:25:15Z","timestamp":1772169915000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Beta cell function and insulin sensitivity during elexacaftor\/tezacaftor\/ivacaftor therapy in people with cystic fibrosis"],"prefix":"10.3389","volume":"17","author":[{"given":"Laura","family":"Zazzeron","sequence":"first","affiliation":[{"name":"Mother and Child Department, Cystic Fibrosis Center, Fondazione Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Ca\u2019 Granda Ospedale Maggiore Policlinico","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Grancini","sequence":"additional","affiliation":[{"name":"Fondazione Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Ca\u2019 Granda Ospedale Maggiore Policlinico, Endocrinology Unit","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maddalena","family":"Trombetta","sequence":"additional","affiliation":[{"name":"Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Hospital Trust of Verona","place":["Verona, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianfranco","family":"Alicandro","sequence":"additional","affiliation":[{"name":"Mother and Child Department, Cystic Fibrosis Center, Fondazione Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Ca\u2019 Granda Ospedale Maggiore Policlinico","place":["Milan, Italy"]},{"name":"Department of Pathophysiology and Transplantation, University of Milan","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Linda","family":"Boselli","sequence":"additional","affiliation":[{"name":"Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Hospital Trust of Verona","place":["Verona, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Cogliati","sequence":"additional","affiliation":[{"name":"Fondazione Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Ca\u2019 Granda Ospedale Maggiore Policlinico, Endocrinology Unit","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Mantovani","sequence":"additional","affiliation":[{"name":"Fondazione Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Ca\u2019 Granda Ospedale Maggiore Policlinico, Endocrinology Unit","place":["Milan, Italy"]},{"name":"Department of Clinical Sciences and Community Health, Dipartimento di Eccellenza 2023-2027, University of Milan","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Gramegna","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology and Transplantation, University of Milan","place":["Milan, Italy"]},{"name":"Internal Medicine Department, Respiratory Unit and Adult Cystic Fibrosis Center, Fondazione Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) C\u00e0 Granda Ospedale Maggiore Policlinico Milan","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Blasi","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology and Transplantation, University of Milan","place":["Milan, Italy"]},{"name":"Internal Medicine Department, Respiratory Unit and Adult Cystic Fibrosis Center, Fondazione Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) C\u00e0 Granda Ospedale Maggiore Policlinico Milan","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo C.","family":"Bonadonna","sequence":"additional","affiliation":[{"name":"Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Hospital Trust of Verona","place":["Verona, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Orsi","sequence":"additional","affiliation":[{"name":"Fondazione Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Ca\u2019 Granda Ospedale Maggiore Policlinico, Endocrinology Unit","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Dacc\u00f2","sequence":"additional","affiliation":[{"name":"Mother and Child Department, Cystic Fibrosis Center, Fondazione Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Ca\u2019 Granda Ospedale Maggiore Policlinico","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2019.08.016","article-title":"Cystic fibrosis related diabetes: Pathophysiology, screening and diagnosis","author":"Granados","year":"2019","journal-title":"J Cyst Fibros"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201512-2518OC","article-title":"Abnormal glucose tolerance in infants and young children with cystic fibrosis","volume":"194","author":"Yi","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"200293","DOI":"10.1183\/16000617.0293-2020","article-title":"Cystic fibrosis-related diabetes and lung disease: an update","volume":"30","author":"Prentice","year":"2021","journal-title":"Eur Respir Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/life13071431","article-title":"Evolving nutritional needs in cystic fibrosis","volume":"13","author":"Frantzen","year":"2023","journal-title":"Life (Basel)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100690","article-title":"German CF Registry of the Mukoviszidose e.V. and participating CF sites. Impact of elexacaftor\/tezacaftor\/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry","volume":"32","author":"Sutharsan","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1159\/000538606","article-title":"Improved nutritional outcomes and gastrointestinal symptoms in adult cystic fibrosis patients treated with elexacaftor\/tezacaftor\/ivacaftor","volume":"42","author":"Stastna","year":"2024","journal-title":"Dig Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/nu13092907","article-title":"The impact of highly effective CFTR modulators on growth and nutrition status","volume":"13","author":"Bass","year":"2021","journal-title":"Nutrients"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2023.1130790","article-title":"Nutritional impact of CFTR modulators in children with cystic fibrosis","volume":"11","author":"Gaschignard","year":"2023","journal-title":"Front Pediatr"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf099","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on glucose tolerance in adolescents with cystic fibrosis","volume":"110","author":"Galderisi","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae857","article-title":"Glycemia and insulin secretion in cystic fibrosis two years after elexacaftor\/tezacaftor\/ivacaftor: PROMISE-ENDO","volume":"110","author":"Chan","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11144149","article-title":"Impact of CFTR modulators on beta-cell function in children and young adults with cystic fibrosis","volume":"11","author":"Piona","year":"2022","journal-title":"J Clin Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/BF03344156","article-title":"Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr)","volume":"29","author":"Cacciari","year":"2006","journal-title":"J Endocrinol Invest"},{"key":"B13","unstructured":""},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1768","article-title":"Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.50.2007.S164","article-title":"A model for glucose control of insulin secretion during 24 h of free living","volume":"50","author":"Mari","year":"2001","journal-title":"Diabetes"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1098\/rsta.2009.0127","article-title":"Selective inference in complex research","volume":"367","author":"Benjamini","year":"2009","journal-title":"Philos Trans A Math Phys Eng Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12026","article-title":"Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study","volume":"14","author":"Bellin","year":"2013","journal-title":"Pediatr Diabetes"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1210\/en.2017-00187","article-title":"CFTR influences beta cell function and insulin secretion through non-cell autonomous exocrine-derived factors","volume":"158","author":"Sun","year":"2017","journal-title":"Endocrinology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcte.2023.100320","article-title":"Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetes","volume":"33","author":"Lurquin","year":"2023","journal-title":"J Clin Transl Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2024.107664","article-title":"Long-term therapy with CFTR modulators consistently improves glucose metabolism in adolescents and adults with cystic fibrosis","volume":"228","author":"Cohen","year":"2024","journal-title":"Respir Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2015.10.012","article-title":"CFTR potentiator therapy ameliorates impaired insulin secretion in CF patients with a gating mutation","volume":"15","author":"Tsabari","year":"2016","journal-title":"J Cyst Fibros"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201806-1018OC","article-title":"Islet hormone and incretin secretion in cystic fibrosis after four months of ivacaftor therapy","volume":"199","author":"Kelly","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-021-01525-4","article-title":"Lumacaftor\/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion","volume":"44","author":"Colombo","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2019.08.004","article-title":"Hypoglycemia in cystic fibrosis: Prevalence, impact and treatment","author":"Moheet","year":"2019","journal-title":"J Cyst Fibros"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1279","article-title":"Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1774728\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:25:16Z","timestamp":1772169916000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1774728\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":25,"alternative-id":["10.3389\/fendo.2026.1774728"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1774728","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"article-number":"1774728"}}